Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...

Coronavirus

Coronavirus

Coronaviruses, including the severe acute respiratory syndrome coronavirus (SARS-CoV), are enveloped viruses characterized by their single-stranded, positive-sense RNA genome and helical nucleocapsid structure. The hallmark of these viruses is their club-shaped spike (S) glycoproteins that protrude from the viral envelope, facilitating attachment to host cells. Typically, coronaviruses infect the upper respiratory tract, often causing mild or asymptomatic disease. However, certain strains like...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Inhibitors Of Virion Release

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Inhibitors of Virion Maturation and Assembly

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

STEMIN- and YAP5SA-induced exosomes prevent cardiomyocyte apoptosis.

iScience·2026

Same author

The body does not keep the score: trauma, predictive coding, and the restoration of metastability.

Frontiers in systems neuroscience·2026

Same author

K<sub>2</sub>P Channels as Key Regulators of Cardiovascular and Pulmonary Vascular Function.

Pharmaceuticals (Basel, Switzerland)·2026

Same author

A medical student's guide to academic anxiety.

Academic medicine : journal of the Association of American Medical Colleges·2026

Same author

Vascular Smooth Muscle-Specific NLRP3 Hyperactivation Drives Arterial Intimal Hyperplasia in Mice.

Research square·2026

Same author

Phosphodiesterase 8 regulation of excitation-contraction coupling as a target for cardiovascular disease: is it my turn now?

American journal of physiology. Heart and circulatory physiology·2026

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

A Small Molecule That In Vitro Neutralizes Infection of SARS-CoV-2 and Its Most Infectious Variants, Delta, and

Arfaxad Reyes-Alcaraz¹, Hanan Qasim¹, Elizabeth Merlinsky¹

¹Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX 77204, USA.

|March 29, 2023

Summary

A new small molecule, CD04872SC, shows promise as a broad-spectrum antiviral against SARS-CoV-2 and its variants. This potential COVID-19 treatment candidate was effective in neutralizing the virus in laboratory studies.

Keywords:

COVID-19 Delta Omicron SARS-CoV-2 spike protein

More Related Videos

Engineering Antiviral Agents via Surface Plasmon Resonance

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Published on: September 8, 2023

Related Experiment Videos

Last Updated: Jul 13, 2026

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

Engineering Antiviral Agents via Surface Plasmon Resonance

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Published on: September 8, 2023

Area of Science:

Virology
Medicinal Chemistry
Drug Discovery

Background:

The COVID-19 pandemic highlights the need for effective antiviral therapies beyond vaccines.
Orally bioavailable, broad-spectrum antivirals are crucial for rapid response to emerging viral threats.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants (Delta, Omicron) remain significant global health concerns.

Purpose of the Study:

To evaluate the antiviral activity of the small molecule CD04872SC against SARS-CoV-2.
To assess the efficacy of CD04872SC against SARS-CoV-2 variants, including Delta and Omicron.

Main Methods:

* In vitro assessment of CD04872SC's neutralizing capacity against SARS-CoV-2.
* Determination of half-maximal effective concentration (EC50) values for the compound against the wild-type virus and its variants.

Main Results:

* CD04872SC demonstrated neutralization of SARS-CoV-2 with an EC50 of 248 μM.
* The compound also inhibited infection by the Delta variant (EC50 = 152 μM) and Omicron variant (EC50 = 308 μM).

Conclusions:

* CD04872SC exhibits broad-spectrum antiviral activity against SARS-CoV-2 and its key variants.
* These findings position CD04872SC as a potential candidate lead for developing novel COVID-19 treatments.